Dr Reddy Share Price Target 2025: Will It Reclaim ₹1,400?
As of August 4, 2025, Dr Reddy’s Laboratories Ltd (NSE: DRREDDY) is trading at approximately ₹1,224.00. The stock is currently consolidating near its support zone of ₹1,200–₹1,230. Based on technical indicators, a bullish breakout could take the stock to ₹1,350–₹1,400 by the end of 2025, while a fall below ₹1,200 may trigger downside risk.
Dr Reddy Share Price Overview
-
Current Price: ₹1,224.00
-
52-Week High/Low: ₹1,421.49 / ₹1,021.1
-
Market Cap: ₹65,000+ Crore
-
Sector: Pharmaceuticals – Generics & Biotech
-
Latest News: Mixed Q1 earnings; positive launch pipeline in the US and India
Technical Analysis Snapshot
Trend Outlook
-
The stock has formed a base near ₹1,220, showing signs of reversal.
-
A break above ₹1,260 could start a new short-term uptrend.
Key Levels to Watch
-
Support Zone: ₹1,200 – ₹1,215
-
Resistance Zone: ₹1,260 – ₹1,280
-
Critical Breakout Point: ₹1,260
Indicators
| Indicator | Status |
|---|---|
| RSI (14-day) | Neutral (~47) – room for upside |
| MACD | Slight bullish crossover developing |
| 200-Day MA | ~₹1,247 – acting as resistance |
| Volume Trend | Stable, low volatility phase |
Dr Reddy Share Price Target 2025
| Scenario | Target Price Range | Trigger Level |
|---|---|---|
| Bullish | ₹1,350 – ₹1,400 | Breakout above ₹1,260 |
| Base Case | ₹1,280 – ₹1,300 | Sustains above ₹1,220 |
| Bearish | ₹1,150 – ₹1,180 | Breaks below ₹1,200 |
What’s Moving the Stock?
Bullish Catalysts
-
New product launches (generic Revlimid, semaglutide)
-
Growth in India & North America formulations
-
Stable margins despite cost pressures
Risk Factors
-
USFDA audit issues at Srikakulam site
-
Pricing pressure in the US generics market
-
Delay in major launches
Analyst Outlook
-
Average Analyst Target: ₹1,284 – ₹1,320
-
Rating: Most analysts have a Buy/Hold view
-
ADR Relative Strength: 81 (above industry average)
